Abstract
The identification of diagnostic, prognostic and predictive biomarkers is an essential task in the development and implementation of treatment in atopic dermatitis (AD). Integrating molecular data from high-quality patient samples with associated clinical data is central to this task. Here, we aimed to investigate associations of AD patients’ skin microbiome, clinical data and treatment response in the TREATgermany registry. Skin swabs of 130 patients were profiled with 16S rRNA amplicon sequencing before and after treatment with dupilumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
